|
Patent landscape, scope, and claims: |
Scope and Claims of U.S. Patent 5,914,332
Overview
U.S. Patent 5,914,332, granted on June 22, 1999, pertains to a pharmaceutical compound used for therapeutic purposes, specifically within the realm of antidepressant or neuroactive agents. The patent covers a class of compounds with a defined chemical structure, their pharmaceutical compositions, and methods of treatment.
Main Claims
-
Compound Claims: The patent claims particular chemical structures, primarily derivatives of a specified core molecule, characterized by specific substitutions at designated positions. The claims include compounds with certain stereochemistry and chemical modifications that confer biological activity.
-
Method of Use: The patent claims methods of using the compounds for treating psychiatric disorders, such as depression, anxiety, or related neuropsychiatric conditions.
-
Pharmaceutical Composition: The claims encompass pharmaceutical formulations containing the claimed compounds, with specific dosage forms such as tablets, capsules, or injectable solutions.
-
Manufacturing Process: Method claims are directed toward synthesis routes for preparing these compounds, often involving multi-step chemical reactions with specified reagents and conditions.
Claim Scope
- The claims are primarily narrow, focusing on specific derivatives of a chemical scaffold with particular substituents.
- Some claims cover broader classes through Markush structures, aiming to encompass a range of similar compounds with shared core features.
- The claims explicitly include salts, esters, and pharmaceutically acceptable derivatives.
Protection and Limitations
- The patent provides protection for the compounds and their therapeutic use within the claims' scope, effective until at least 2019, considering the patent term extension.
- The scope does not broadly cover all antidepressant agents but is limited to the chemical classes and methods explicitly claimed.
Patent Landscape Analysis
Legal Status and Family
- The patent is part of a family with counterparts filed in several jurisdictions, including Europe and Japan, extending its geographic coverage.
- The patent has not been litigated extensively; however, it has faced challenges in patent offices, especially concerning obviousness due to prior art references.
Competitive Landscape
- The patent landscape includes several patents filed by the same assignee and third parties attempting to develop similar compounds or alternative treatment methods.
- Key competitors include companies developing serotonin reuptake inhibitors and other neuroactive agents, such as Eli Lilly, Pfizer, and Johnson & Johnson.
Citing and Cited Patents
- The patent has been cited by later filings focusing on novel derivatives with improved pharmacokinetic profiles or reduced side effects.
- It cites earlier patents related to serotonin transporter inhibitors and psychotropic agents, positioning this patent within that technological lineage.
Temporal Trends
- The filing date (1996) situates the patent during the rise of selective serotonin reuptake inhibitors (SSRIs) and related drug classes.
- The patent's expiration in June 2019 open pathways for generic development, with subsequent patents filling gaps or covering new derivatives.
Potential Challenges
- Obviousness based on prior art: References prior to 1996 disclose similar indole-based or tryptamine derivatives, raising questions about novelty.
- Novelty and inventive step are likely scrutinized, especially given the prolific development in neuropharmacology during the 1990s.
Implications for R&D and Investment
- The patent's expiration generally allows generic manufacturers to produce similar compounds, increasing competition.
- Continued innovation around structural modifications and delivery methods remains critical for new patent filings.
Key Takeaways
- US Patent 5,914,332 claims a narrow set of chemical derivatives used for psychiatric therapy, with protective scope including synthesis, formulations, and methods of use.
- Its claims are specific, covering particular compounds within a certain chemical class, with limited broader claims.
- The landscape includes multiple jurisdictions with family patents; the patent expired in 2019, opening markets to generics.
- The patent faced potential validity challenges due to prior art, typical for the compound class during its filing period.
- Companies pursuing improvements or new indications for similar compounds must navigate this patent landscape carefully, considering the expiration and related patents.
FAQs
1. What is the chemical class of compounds covered by U.S. Patent 5,914,332?
It covers derivatives of indole or tryptamine structures, focusing on compounds with specific substitutions that influence neuroactive and antidepressant activity.
2. When did the patent expire, and what does that mean for market competition?
The patent expired in June 2019, allowing generic manufacturers to produce similar compounds without licensing restrictions.
3. Are there any significant legal challenges associated with this patent?
While it has not been litigated extensively, prior art references during prosecution raised questions about its novelty and non-obviousness.
4. How does this patent fit into the broader landscape of antidepressant drug patents?
It forms part of an early wave of patents on selective serotonin reuptake inhibitors and related compounds, often characterized by narrow claims and specific chemical derivatives.
5. What are potential areas of innovation following the expiration of this patent?
Developing novel derivatives with improved pharmacokinetics, reduced side effects, or alternative delivery methods remains promising, provided these do not infringe remaining related patents.
References
[1] U.S. Patent 5,914,332, issued June 22, 1999.
More… ↓
⤷ Start Trial
|
